These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35301645)

  • 1. Targeted therapies in the medical management of craniopharyngioma.
    Iglesias P
    Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 4. The Medical Therapy of Craniopharyngiomas: The Way Ahead.
    Alexandraki KI; Kaltsas GA; Karavitaki N; Grossman AB
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5751-5764. PubMed ID: 31369091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
    Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
    Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
    Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
    Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
    He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
    Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
    Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A
    Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
    Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
    J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.
    Wu ZP; Wang YL; Wang LC; Liu ZY; Fan RR; Zan X; Liang RC; Yang JL; Zhou LX; Xu JG
    World Neurosurg; 2023 Dec; 180():e117-e126. PubMed ID: 37683921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
    Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
    Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes].
    Fujio S; Hanaya R
    No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
    Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
    Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological Behaviour of Craniopharyngiomas.
    Martinez-Barbera JP; Andoniadou CL
    Neuroendocrinology; 2020; 110(9-10):797-804. PubMed ID: 32126562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
    Roque A; Odia Y
    CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.
    Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O
    CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.
    Losa M; Mazza E; Pedone E; Nocera G; Liscia N; Reni M; Mortini P
    J Endocrinol Invest; 2024 Nov; 47(11):2835-2842. PubMed ID: 38696125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.
    Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J
    Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
    Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
    Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.